---
document_datetime: 2023-09-21 18:02:43
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/pumarix-epar-all-authorised-presentations_en.pdf
document_name: pumarix-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7399732
conversion_datetime: 2025-12-21 16:04:37.0762
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| EU Number       | Invented name   | Strength   | Pharmaceutical                                          | Route of                         | Packaging                                             | Content                                              | Package size                                    |
|-----------------|-----------------|------------|---------------------------------------------------------|----------------------------------|-------------------------------------------------------|------------------------------------------------------|-------------------------------------------------|
| EU/1/10/664/001 | Pumarix         | -- 1       | Form Suspension and emulsion for emulsion for injection | Administration Intramuscular use | suspension (H5N1): vial (glass); emulsion (adjuvant): | (concentration) suspension: 2.5 ml; emulsion: 2.5 ml | 50 vials (suspension) + 2 x 25 vials (emulsion) |

1/1 \\_ \\_1 3.75 µg HA After mixing, 1 dose (0.5 ml) contains: Split influenza virus inactivated, containing antigen* equivalent to: A/Indonesia/05/2005 (H5N1) 3.75 micrograms** * propagated in eggs ** haemagglutinin AS03 adjuvant composed of squalene (10.69 milligrams), DLα -tocopherol (11.86 milligrams) and polysorbate 80 (4.86 milligrams) Medicinal product no longer authorised